Author:
Eilsberger Friederike,Luster Markus
Publisher
Springer Berlin Heidelberg
Reference66 articles.
1. Beak JH, Kim YS, Sung JY et al (2011) Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 197(2):W331–W336
2. Benua RS, Cicale NR, Sonenberg M et al (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Therapy, Nucl Med 87:171e82
3. Berdelou A, Borget I, Godbert Y et al (2017) Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid. https://doi.org/10.1089/thy.2017.0205
4. Bernier MO, Leenhardt L, Hoang C et al (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573
5. Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319–328